Icecure Medical is trading 14.96% up in after-hours trading at $1.46, with no clear catalyst identified. - The stock closed the regular session at $1.27 and fell during the session while major indexes rose, leaving a broader-market explanation uncertain. - On October 6, the company announced that Legacy Health joined its FDA-approved ChoICE post-market study. - The study is expected to enroll about 400 patients at up to 30 U.S. sites; available reports do not establish that the announcement caused the after-hours move.